Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01647568

Enrollment

715

Registered

2012-07-23

Start date

2009-12-31

Completion date

Unknown

Last updated

2012-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-platelet Therapy, Colonoscopy, Post-polypectomy Bleeding

Brief summary

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy. Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients presenting to the GI lab for elective colonoscopy

Exclusion criteria

* Patients on Coumadin or other anti-coagulants * Patients with Inflammatory Bowel Disease

Countries

United States

Outcome results